DOCUMENT
A -- NHLBI Proteomic Centers - Solicitation 1
- Notice Date
- 1/26/2009
- Notice Type
- Solicitation 1
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-HV-10-05_(2)
- Response Due
- 1/24/2009
- Archive Date
- 1/15/2010
- Point of Contact
- Michelle Kouis,, Phone: (301) 435-0340, Joanne F Deshler,, Phone: (301) 435-0340
- E-Mail Address
-
kouisma@nhlbi.nih.gov, deshlerj@nhlbi.nih.gov
- Small Business Set-Aside
- N/A
- Description
- The National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), Office of Acquisitions (OA), will be seeking proposals from Proteomic Center contractors to develop and enhance proteomic technologies and use them to gain a greater understanding of physiological pathways, molecular interactions, and regulatory signals, as well as begin to apply the technologies and knowledge to clinical questions. Each NHLBI Proteomic Center contractor will integrate expertise in multiple disciplines (proteomics, physiology, clinical studies, molecular biology, genomics, chemistry, physics, engineering, computational biology, bioinformatics, and biostatistics) to advance proteomic applications in heart, lung, blood, and sleep diseases and disorders. Each NHLBI Proteomic Center contractor will identify and address a specific clinical need/problem/disease/process (see examples directly below) using three components that make an interactive team: 1) proteomic technology development; 2) mechanistic and functional understanding of the proteome, its interactions and dynamics and 3) clinical application of proteomic approaches and discoveries. The components should be interdependent and drive each others science and progress. Examples include, but are not limited to: Transplantation Develop novel approaches for measuring the proteome, subproteome, and/or post translational modification (PTM) that will predict rejection; study the interaction and pathways of these molecules; and measure the unique proteome, subproteome or PTMs in patient samples in order to model outcome or improve treatment predictions. Cardiac hypertrophy and heart failure Develop innovative proteomic technologies and computational approaches (e.g., to model and integrate multiple data types from genomic and proteomic studies) and apply them to the discovery of clinically-useful markers of adverse cardiac remodeling; develop technologies, methods and probes (e.g., high-affinity ligands, antibodies, etc.) to measure and quantify the presence of such markers in biological samples or in the body (e.g., using imaging probes) for early diagnosis or to assess therapy efficacy. Myocardial ischemia Develop technologies and methods to identify biomarkers (e.g., proteins, polypeptides, PTMs) for early detection and diagnosis of myocardial ischemia; test technologies and methods in at-risk populations. Thrombosis Develop proteomic profiling methodologies to identify patterns for thromoembolic risk stratification; examine pathways underlying the expression patterns using novel protein interaction and modification technologies; test patterns in patient samples to model risk for development or recurrence of a thromboembolic event. Atherosclerosis Predict and measure molecular determinants of plaque stability and vulnerability; develop risk prediction assays for plaque rupture in acute coronary syndrome patients and in patients presenting with shortness of breath and chest pain. Arrhythmias and sudden cardiac death: Develop innovative methods and approaches to identify proteins, peptides, post-translation modifications, or other biomarkers to identify those at highest and lowest risk of developing potentially fatal cardiac arrhythmias in patients with implantable cardioverter defibrillators (ICDs); access these approaches in model systems and human samples. Chronic obstructive pulmonary disease (COPD) Develop approaches for expression profiling; determine molecular phenotype of COPD using protein expression profiles of epithelial cells from bronchoalveolar lavage; model and develop standardized molecular phenotype profiles in patients to determine treatment course. Pulmonary arterial hypertension (PAH) - Develop tools and applications for the discovery of protein expression profiles or biomarkers that are associated with PAH; test the findings retrospectively or prospectively in any clinical study of PAH. Sleep apnea - Develop tools and approaches for the discovery of biomarkers of sleep apnea and biological timing; study sleep apnea with other co-morbid conditions (e.g., a variety of cardiovascular and metabolic abnormalities) that could facilitate the elucidation of pathophysiological mechanisms of sleep apnea and other conditions as well. Hemoglobinopthies: Develop tools and approaches to better understand protein profiles for the altered red cell function due to mutations in various membrane or skeletal proteins; discover and test biomarkers for modifier genes that define susceptibility to stroke in sickle cell patients. Bone marrow failure: Develop tools and applications for the discovery of protein expression profiles or biomarkers for ribosomal proteins associated with erythroid bone marrow defect and other related bone marrow failure disorders; model and test pathways that could lead to prediction, prevention, and treatment strategies. Each Proteomic Center will be expected to enhance proteomic tools and technologies with the goal of using them for mechanistic and functional understanding of heart, lung, blood, and sleep diseases and disorders. Enhancement of proteomic tools and technologies can include hardware or software to improve the measurement, characterization, or comparison of proteins, peptides, PTMs, isoforms, genomic/epigenomic tags, small molecules, or other related cellular or tissue components. Mechanistic and functional understanding can include, but is not limited to, experimental and/or computational approaches to molecular function/dysfunction, dynamics, interactions, pathways, process, transport, or other related actions, in cells, tissues, organs, and whole organisms. The Centers should also work with an eye toward clinical studies using the proteomic tools, technologies, mechanisms, and functional understanding to guide human subject studies. It is expected that all Centers will have human research studies during the course of the project period. The Centers should leverage existing resources to support these human subject studies, such as CTSA, clinical networks, ongoing clinical trials, ongoing cohort studies, and industry supported studies. It is critical that the funded Centers interact to share information on technical objectives, progress and impediments, as well as exchange ideas, and, where appropriate, establish collaborations. Thus, all research products and results must be made available to the research community in a timely fashion. Each Center will have a project plan that will address milestones, deliverables, and sharing. A Progress Review Panel will provide feedback and advice to both the Centers and to NHLBI. THIS PRESOLICITATION NOTICE IS NOT THE REQUEST FOR PROPOSALS (RFP); the Request For Proposals will be available on or about January 26, 2009. This solicitation will not be open to Federally Funded Research Development Centers (FFRDCs). JANUARY 26, 2009 - THIS NOTICE HAS BEEN UPDATED TO INCLUDE THE ACTUAL SOLICITATION. ALL PROPOSALS IN RESPONSE TO THIS SOLICITATION ARE DUE MAY 20, 2009, WITH THE PROPOSAL INTENT RESPONSE DUE ON APRIL 20, 2009 (SEE ATTACHED RFP DOCUMENTS FOR FURTHER DETAILS).
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=2050ba018e708a52a73b5fdb9104ed16&tab=core&_cview=1)
- Document(s)
- Solicitation 1
- File Name: RFP (NHLBI Proteomic Centers RFP No. NHLBI-HV-10-05_(2).pdf)
- Link: https://www.fbo.gov//utils/view?id=2c099ad77b69869cdcca79c0a842d262
- Bytes: 574.18 Kb
- File Name: Attachment 1 - Additional RFP Instructions (BAA_NHLBI-HV-10-05_(2)_Attachment_1.pdf)
- Link: https://www.fbo.gov//utils/view?id=a1c66140dc9ea30a248d23b0945de38c
- Bytes: 102.71 Kb
- File Name: Attachment 2 - Past Performance (PPQ.pdf)
- Link: https://www.fbo.gov//utils/view?id=6501f0dfd65125c623a2e57d7da544ff
- Bytes: 30.73 Kb
- Note: If links are broken, refer to Point of Contact above or contact the FBO Help Desk at 877-472-3779.
- File Name: RFP (NHLBI Proteomic Centers RFP No. NHLBI-HV-10-05_(2).pdf)
- Record
- SN01737951-W 20090128/090126215102-2050ba018e708a52a73b5fdb9104ed16 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |